Welcome to NeurologyLive®‘s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®‘s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: FDA Action Update, April 2024: Approvals, Clearance, and Complete Response Letter
The FDA was busy in April 2024, making a number of decisions on potential new therapeutic agents including granting approvals, a clearance, and a fast track designation, issuing a complete response letter, and agreeing to a new specialized protocol for a clinical trial.
2: Recent Progress in Advancing Gene Therapy for Parkinson Disease: Russell Lonser, MD
The director of the Gene Therapy Institute at The Ohio State University discussed the key challenges in optimizing gene therapy for Parkinson disease (PD), particularly regarding target selection and gene choice. He also spoke about how findings from the recent phase 1b trial further contribute to the understanding of the potential of gene therapy’s efficacy and safety in treating PD.
3: Apple’s May 7th Event Could Introduce OLED iPads, A Game-Changer for Older Adults and Those with Neurological Disorders
Neal K. Shah, CEO of CareYaya Health Technologies, discussed how Apple’s expected announcement of new iPads with OLED displays could revolutionize cognitive health and dementia care for older adults. He highlights the benefits of OLED technology, such as lower blue light emissions, reduced eye strain, enhanced readability, and the potential for adaptive interfaces, all of which could significantly improve the effectiveness of digital therapeutics.
4: NeuroVoices: Kayla Scippa, on Recognizing Unmet Need in Chronic Demyelinating Polyneuropathy
In this week’s NeuroVocies Q&A, Kayla Scippa, the associate director of Patient Reported Outcomes at Johnson & Johnson, provided clarity on a poster presentation from the 2024 American Academy of Neurology (AAN) Annual Meeting, held April 13-18, in Denver, Colorado, examining the most critical aspects to chronic demyelinating polyneuropathy disease severity.
5: Apolipoprotein E4 in Alzheimer’s Disease
In episode 1 of the Peer Exchange video series titled “Preparing for a New Era in Alzheimer’s Disease: Debating New Targeted Biomarkers and Therapeutic Approaches”, Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer disease, and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.
